Breaking Finance News

Beaufort Securities disclosed GlaxoSmithKline PLC (LON:GSK), maintaining its target at 1,800.00GBX earlier today

Just yesterday GlaxoSmithKline PLC (LON:GSK) traded -0.01% lower at 1,521.75GBX. The company’s 50-day moving average is 1,502.15GBX and its 200-day moving average is 1,580.48GBX. The last stock close price is down -3.62% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same time period. 238,842 shares of GSK traded, down from an average trading volume of 7,975,860

Beaufort Securities hold steady the price target of GlaxoSmithKline PLC (LON:GSK) at 1,800.00GBX reporting a potential upside of 0.18%.

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

With a total market value of 0 GBX, GlaxoSmithKline PLC has price-earnings ratio of 38.96 with a one year low of 1,444.00GBX and a one year high of 1,724.50GBX .

A total of 24 brokers have issued a research note on the company. Three equity analysts rating the company a strong buy, six analysts rating the company a buy, seventeen analysts rating the company a hold, two analysts rating the company a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of 1,577.33GBX.

General Company Details For GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.